Results 71 to 80 of about 820 (140)

Forgotten Steps in the Coagulation Cascade

Haemophilia, EarlyView.
Quentin Van Thillo, Cedric Hermans
wiley   +1 more source

Biologics and Drug‐Induced Immunogenicity: A Case Report of Acquired Hemophilia A Presenting After Immunotherapy

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Acquired hemophilia A is a rare, potentially life‐threatening bleeding disorder caused by autoantibody inhibitors to coagulation factor VIII. We report the case of an 87‐year‐old female who presented with symptomatic bleeding and was subsequently diagnosed with acquired hemophilia A.
Kevin A. Murgas, Sundus Nasim, Stephen Poos, Jules A. Cohen, Anna Andrzejczyk   +4 more
wiley   +1 more source

Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A

Hematology Reports
Background: Acquired hemophilia A (AHA) is a bleeding disorder caused by autoantibodies against coagulation factor VIII. Treatment includes controlling bleeding and eliminating the inhibitor.
Hikari Ota, Kyohei Yasuda, Namie Toyota, Kazuhiro Masuoka   +3 more
doaj   +1 more source

Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders

Haemophilia, Volume 32, Issue 3, Page 691-698, May/June 2026.
ABSTRACT Introduction Joint bleeds are burdensome and recovery differs from bleed to bleed. Identifying predictors of recovery could enable personalized treatment and monitoring; aiming to prevent long‐term joint deterioration, and facilitate faster return to activities. Aim To identify predictors of time to recovery after joint bleeding in people with
Gijs Aertssen, Lize F. D. van Vulpen, Wouter Foppen, Flora H. P. van Leeuwen, Merel A. Timmer   +4 more
wiley   +1 more source

Channeling effects in the prescription of new therapies:the case of emicizumab for hemophilia A

, 2022
Aim: To determine if emicizumab was channeled to clinically complex people with hemophilia A upon approval. Methods: Claims data (16 November 2017, through 31 December 2019) from US-based insurance databases were analyzed to compare the clinical ...
Faghmous, Imi, Kuebler, Peter, Howard, Monet, Xu, Tao, Nissen, Francis, Flores, Carlos, Mahajerin, Arash, Chang, Tiffany   +7 more
core   +1 more source

Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors [PDF]

Background Guidelines surrounding emicizumab prophylaxis and perioperative treatment for people with hemophilia A (PwHA) with factor (F)VIII inhibitors undergoing surgeries are limited. The phase IIIb multicenter, single-arm STASEY study evaluated safety
Roger E.G. Schutgens, Kremer Hovinga, Johanna A, Johanna A. Kremer Hovinga, Susan Robson, Peyvandi, Flora, Flora Peyvandi, Castaman, Giancarlo, Schutgens, Roger E G, Kremer Hovinga, Johanna A., Robson, Susan, Katya Moreno, Víctor Jiménez-Yuste, Schutgens, Roger E. G., Jiménez-Yuste, Víctor, Moreno, Katya, Giancarlo Castaman   +15 more
core   +1 more source

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

, 2021
Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking.
Ivan Budnik, Einat Avishai, Mudi Misgav, Sarina Levy-Mendelovich, Tami Brutman-Barazani, Gili Kenet, Tamara Levy, Tami Livnat, Assaf A. Barg   +8 more
core   +1 more source

Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry

Research and Practice in Thrombosis and Haemostasis
Background: Nonfactor therapy with emicizumab has become an important part of the haemophilia A treatment landscape recently. Objectives: We aimed to analyze data on the transition from previous treatment regimens to emicizumab in routine clinical ...
Ester Zápotocká, Petra Ovesná, Bohumír Blažek, Zuzana Čermáková, Zdeňka Hajšmanová, Radomíra Hrdličková, Petr Birke, Daniela Procházková, Petr Smejkal, Jan Blatný   +9 more
doaj   +1 more source

Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors

, 2022
To assess real-world use of emicizumab in adult people with hemophilia A (PwHA) without inhibitors including healthcare resource utilization (HCRU) and costs.
Jennifer Thorburn (13112730), David Hinds (570153), Lorraine Cafuir (13112724), Patricia Prince (10224193), Adina Estrin (13112727), Er Chen (5198534), Christine L. Kempton (10332563), Henry Mead (13112733)   +7 more
core   +1 more source

The impact of higher concentrations of FIX and FX on determination of emicizumab plasma level.

, 2022
FVIII-deficient plasma was spiked with FIX (A) or FX (B) to reach 100%, 150% and 200% of normal plasma levels in molarity. Then samples were spiked with emicizumab (● indicates 100 μg/ml emicizumab; ■ 10 μg/ml emicizumab and ▲ without emicizumab).
Johannes Oldenburg (138185), Jens Müller (263387), Bernd Pötzsch (615446), Nasim Shahidi Hamedani (13046936)   +3 more
core   +1 more source